Drug-enhanced sports: 'Clown show' or the future?

The Enhanced Games, backed by Peter Thiel, 1789 Capital and other investors, will debut on May 24 in Las Vegas with more than 40 athletes and prize money of up to $1 million for world-record performances. The event is designed to openly allow performance-enhancing drugs under medical supervision, triggering backlash from the IOC, WADA and other sports bodies over safety, fairness and anti-doping norms. The company also plans to use the event to promote telehealth and longevity products such as testosterone, peptides, GLP-1s and NAD+, and recently began trading on the NYSE.

Analysis

This is less a sports story than an attention-arbitrage play with regulatory optionality. The biggest near-term beneficiary is not the athletes’ legacy brands but the platform/distribution layer: any event that can manufacture controversy, clips, and creator-style virality has asymmetric value for streaming intermediaries and ad-tech because the audience is discovery-driven rather than loyalty-driven. The per-ticker signal still favors ROKU over PYPL/PLTR on directness: Roku can monetize live niche inventory with low incremental CAC, while the event’s socially shareable format gives it a better chance of producing repeat viewing than a one-off curiosity.

The second-order issue is that the commercialization angle may outlast the novelty of the competition itself. If the company can convert even a small share of event viewers into telehealth leads, it gets a funnel economics story that investors may misread as “sports branding” when it is really a regulated consumer-health acquisition engine. That makes the real risk to the equity story less moral backlash and more FDA/advertising scrutiny: if regulators constrain peptide/GLP-1 marketing claims, the enterprise value multiple compresses quickly because the event alone is not enough to justify a durable platform.

Contrarian view: consensus is likely overestimating the reputational toxicity and underestimating the investable niche. The backlash helps create a clear identity, and controversial categories often generate a more efficient CAC than bland wellness brands. The bigger medium-term swing factor is whether mainstream sports bodies enforce a hard exclusion policy, because if athletes can’t plausibly return to sanctioned competition, the talent pool narrows and the event degrades from “alternative league” to stunt, with the monetization thesis shifting from recurring media to one-shot speculation. For PLTR, there is no material direct read-through; any bid is likely just thematic sympathy with “future of human performance” hype, not fundamentals.

Key Decisions for Investors

• Long ROKU into the event weekend / next 1-3 sessions: trade the probability of elevated live-stream engagement and low-cost ad inventory monetization; take profit on a 5-8% move, cut if social interest fails to sustain by the first 48 hours.
• Short PYPL on a 1-3 month horizon if the market starts attributing any fintech-adjacent “infrastructure” premium to the launch narrative; there is no clear transaction rail exposure, so any sympathy rally should fade. Use a tight stop above the event-driven momentum high.
• Avoid PLTR as a thematic long; if anything, sell call spreads on any hype-driven bounce over the next 2-4 weeks because the connection is narrative-only and the stock can gap on low-quality theme flows, but lacks fundamental linkage.
• If available, consider a long ROKU / short broader media ETF pair for 2-6 weeks: the event-specific live-content angle can outperform passive media names without requiring a durable broad ad-spend rebound.
• Optionality trade: buy short-dated ROKU calls only against a defined premium budget into the first weekend of livestreams; the setup is a volatility event, not a multi-quarter thesis, so size for binary attention spikes rather than valuation rerating.